Progress report. Cytotoxic therapy for gastrointestinal carcinoma.
D000230:Adenocarcinoma / Q000188:drug therapy; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D001761:Bleomycin / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D003680:Deglutition Disorders / Q000209:etiology; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D004938:Esophageal Neoplasms / Q000188:drug therapy; D005472:Fluorouracil / Q000627:therapeutic use; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy; D008937:Mitomycins / Q000627:therapeutic use; D009362:Neoplasm Metastasis; D009607:Nitrosourea Compounds / Q000627:therapeutic use; D011878:Radiotherapy / Q000009:adverse effects; D013311:Streptozocin / Q000627:therapeutic use
D000903:Antibiotics, Antineoplastic; D000964:Antimetabolites, Antineoplastic; D008937:Mitomycins; D009607:Nitrosourea Compounds; D001761:Bleomycin; D013311:Streptozocin; D005472:Fluorouracil